DK1202725T3 - Metode til behandling af symptomer på hormonal variation, herunder hedeture - Google Patents

Metode til behandling af symptomer på hormonal variation, herunder hedeture

Info

Publication number
DK1202725T3
DK1202725T3 DK00948900T DK00948900T DK1202725T3 DK 1202725 T3 DK1202725 T3 DK 1202725T3 DK 00948900 T DK00948900 T DK 00948900T DK 00948900 T DK00948900 T DK 00948900T DK 1202725 T3 DK1202725 T3 DK 1202725T3
Authority
DK
Denmark
Prior art keywords
compound
hot flashes
treating
hormonal variation
patient
Prior art date
Application number
DK00948900T
Other languages
English (en)
Inventor
Thomas J Guttoso Jr
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester filed Critical Univ Rochester
Application granted granted Critical
Publication of DK1202725T3 publication Critical patent/DK1202725T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
DK00948900T 1999-07-22 2000-07-21 Metode til behandling af symptomer på hormonal variation, herunder hedeture DK1202725T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14506199P 1999-07-22 1999-07-22
PCT/US2000/020046 WO2001007037A1 (en) 1999-07-22 2000-07-21 Method of treating symptoms of hormonal variation, including hot flashes

Publications (1)

Publication Number Publication Date
DK1202725T3 true DK1202725T3 (da) 2007-07-23

Family

ID=22511431

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00948900T DK1202725T3 (da) 1999-07-22 2000-07-21 Metode til behandling af symptomer på hormonal variation, herunder hedeture

Country Status (12)

Country Link
US (1) US6310098B1 (da)
EP (1) EP1202725B1 (da)
AT (1) ATE359068T1 (da)
AU (1) AU767119B2 (da)
CA (1) CA2378918C (da)
CY (1) CY1107623T1 (da)
DE (1) DE60034344T2 (da)
DK (1) DK1202725T3 (da)
ES (1) ES2287021T3 (da)
NZ (1) NZ517044A (da)
PT (1) PT1202725E (da)
WO (1) WO2001007037A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080207755A1 (en) * 2000-05-31 2008-08-28 Pfizer Inc Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
DE60209152T2 (de) 2001-09-03 2006-08-03 Newron Pharmaceuticals S.P.A. Pharmazeutische zusammensetzung, umfassend gabapentin oder ein analogon davon und ein alpha-aminoamid
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP1575501A2 (en) * 2002-07-12 2005-09-21 University of Rochester Use of amino acids for treatment of various conditions
US20040092519A1 (en) * 2002-08-14 2004-05-13 Fred Hassan New treatment for hot flashes
KR20050085636A (ko) * 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 섬유근육통 및 기타 질환의 치료를 위한 프레가발린 유도체
MXPA05010515A (es) 2003-03-31 2006-03-10 Xenoport Inc Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
WO2005025562A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
WO2005027850A2 (en) * 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
KR101096480B1 (ko) 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
AU2005301970B2 (en) * 2004-11-04 2011-06-02 Arbor Pharmaceuticals, Llc Gabapentin prodrug sustained release oral dosage forms
RS54522B1 (en) 2005-12-22 2016-06-30 Newron Pharmaceuticals S.P.A. 2-Phenylethylamino Derivatives as Modulators of Calcium and (or Sodium) Channels
AU2006332690A1 (en) * 2005-12-29 2007-07-12 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
US8420624B2 (en) * 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
WO2009102734A1 (en) * 2008-02-11 2009-08-20 Depomed Inc. Methods for treating vasomotor symptoms using gaba analogs in a gastric retentive dosage form
SG176464A1 (en) 2008-05-09 2011-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CN102223893B (zh) 2008-07-22 2014-07-16 曼诺吉尼克斯公司 治疗与绝经、激素改变和关节炎相关的症状的组合物和方法
US9151289B2 (en) 2008-08-21 2015-10-06 Cummins Inc. Fuel pump
US8461102B2 (en) * 2010-03-02 2013-06-11 George E. Royster, JR. Methods and compositions for treating and preventing symptoms of hormonal variations
ES2574210T3 (es) * 2010-03-02 2016-06-15 Fervent Pharmaceuticals, Llc Métodos y composiciones para tratar o prevenir los síntomas de las variaciones hormonales
WO2018015946A1 (en) 2016-07-17 2018-01-25 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
JP2022532851A (ja) * 2019-04-22 2022-07-20 エル クノブラー、ロバート ホットフラッシュの非ホルモン治療

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960931A (en) 1988-05-02 1990-10-02 Warner-Lambert Company Gabapentin mohohydrate and a process for producing the same
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
GB9308430D0 (en) * 1993-04-23 1993-06-09 Glaxo Group Ltd Medicaments
AU731279B2 (en) 1996-03-14 2001-03-29 Warner-Lambert Company Novel bridged cyclic amino acids as pharmaceutical agents
HRP980342A2 (en) 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
AU8668598A (en) 1997-08-20 1999-03-08 University Of Oklahoma, The Gaba analogs to prevent and treat gastrointestinal damage
US5962505A (en) 1998-08-31 1999-10-05 Bobrove; Arthur M. Method for treating hot flashes in humans
AU3735000A (en) * 1999-05-05 2000-11-21 Warner-Lambert Company Modulation of substance p by gaba analogs and methods relating thereto

Also Published As

Publication number Publication date
US6310098B1 (en) 2001-10-30
NZ517044A (en) 2004-02-27
PT1202725E (pt) 2007-07-11
ATE359068T1 (de) 2007-05-15
CA2378918C (en) 2007-01-23
AU767119B2 (en) 2003-10-30
AU6233000A (en) 2001-02-13
CY1107623T1 (el) 2013-03-13
EP1202725A4 (en) 2004-02-04
EP1202725A1 (en) 2002-05-08
DE60034344D1 (de) 2007-05-24
ES2287021T3 (es) 2007-12-16
CA2378918A1 (en) 2001-02-01
WO2001007037A1 (en) 2001-02-01
DE60034344T2 (de) 2008-01-10
EP1202725B1 (en) 2007-04-11

Similar Documents

Publication Publication Date Title
DK1202725T3 (da) Metode til behandling af symptomer på hormonal variation, herunder hedeture
EE05419B1 (et) Asendatud oksasolidinoonid kombineeritud raviks
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
ATE457166T1 (de) Orale zusammensetzungen zur behandlung von diabetes
CY1105199T1 (el) Θepαπευτικες συνθεσεις για αντιμετωπιση της υπepεκκρισης βλεννας
BR0008687A (pt) Métodos para o tratamento de, e para prevenir ou controlar, distúrbios gastrointestinais, disfunção da motilidade gastrointestinal, emese, e doença de refluxo gastro-esofageano em um paciente, e, composição farmacêutica
CO5670356A2 (es) Programa de dosificaicon para un nuevo agente anticanceroso
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
FI971172A (fi) Menetelmä annosyksikköjen valmistamiseksi märkärakeistamalla
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR9509807A (pt) Composição líquida para administração oral e processo para tratar um mamífero incluindo o homem que esteja sofrendo de um quadro clinico mediado pela aç o do 5ht nos receptores 5ht3
DK1401422T3 (da) Halogenholdig sammensætning, fremgangsmåde til fremstilling heraf og anvendelser heraf
BR0313718A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
BR0105787A (pt) Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico
BR0203267A (pt) Combinações farmacêuticas para o tratamento de doenças neurodegenerativas
EA200101240A1 (ru) Использование мелатонина в медицине
DK0762883T3 (da) Pyridylbisphosphonater til anvendelse som terapeutisk middel
BR0309032A (pt) Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores
BR0111900A (pt) Uso de um antagonista do receptor do tipo 1 da angiotensina ii, formulação farmacêutica, e, métodos para o tratamento de uma condição de cefaléia vascular e para o tratamento de enxaqueca
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
NO20032411L (no) Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens
BR0308517A (pt) Combinação de um antagonista do receptor de aldosterona e de um agente sequestrante de ácido biliar
BR0016646A (pt) Método para tratar um paciente que sofre de dor, e, composição farmacêutica
ATE271867T1 (de) Behandlung der harninkontinenz und zusammenstellung dafür